Executive Summary
The Global Plasma Protein Therapeutics Market is estimated at USD 25.4 billion in the year 2020. New plasma-derived therapies is the primary driving factor for the global plasma protein therapeutics market.
Increasing introduction of new plasma-derived therapies with increasing use of Plasma Protein Therapeutics in pharmaceuticals, which are effectively used to treat various diseases like hemostasis and growing awareness on the utilization of various components in the laboratories that are highly effective and promote a modernized way of treatment procedures significantly influences the demand of the global Plasma Protein Therapeutics market.
The plasma protein therapeutics market is also driven by rising incidences of genetic disorder diseases worldwide. Moreover, the trends towards detecting the diseases at an early stage by diagnosing as early as possible is enhancing the growth of the market. From the past two decades, the demand for targeted therapies is growing tremendously, which is solely to level up the growth rate of the market. These factors are additionally fuelling the growth of the overall plasma protein market globally.
Furthermore, the market is experiencing a surge in the demand of advanced therapeutic remedies being developed from the plasma protein because of its effective advantages, thereby driving the growth of the market. Furthermore, the government aids toward the advancing healthcare industry and the favorable reimbursement policies by the health policy investment companies also facilitating the growth of the market.
Scope of the Report
• The report presents the analysis of Clear Aligner market for the historical period 2016-2020 and forecast period of 2021-2026.
• The report analyses the Peptides Therapeutic Market by value (USD Million).
• The report analyses the Peptides Therapeutic Market by Product (Immunoglobulin, Albumin, Factor VIII, Others).
• The report analyses the Peptides Therapeutic Market by Application (Hemophilia, PID, ITP, Others).
• The Global Peptides Therapeutic Market has been analysed By Region (North America, Europe, Asia Pacific and LAMEA) By Country (United States, Canada, Germany, U.K, France, Spain, China, Japan, Australia and South Korea).
• The key insights of the report have been presented through the frameworks of the attractiveness of the market has been presented by region, by Product, by Application.
• Also, the major opportunities, trends, drivers and challenges of the industry has been analysed in the report.
• The report tracks competitive developments, strategies, mergers and acquisitions and new product development. The companies analysed in the report include CSL Behring, Baxter International Inc., Takeda Pharmaceutical Company Limited, Biotest AG, Bayer Group, Grifols, S.A., Pfizer, OCTA Pharma, Kedrion bio Pharma, ADMA biologics, Inc.
Key Target Audience
• Biotechnology Companies
• Pharmaceutical Companies
• Consulting and Advisory Firms
• Government and Policy Makers
• Regulatory Authorities
List of Figures
Figure 1: Global Plasma Protein Therapeutics Market Size, By Value, 2016-2026 (USD Million)
Figure 2: Global Demand growth for immunoglobulin in select developed countries in 2018
Figure 3: Global GDP per Capita Growth (annual %), 2015-2019
Figure 4: World Population 65 Years & Above (% of Total), 2015-2019
Figure 5: Global Current Healthcare Expenditure as % of GDP, 2015-2018 (In %
Figure 6: Global Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)
Figure 7: Global Plasma Protein Therapeutics Market- By Product Market Share, 2020 & 2026
Figure 8: Global Plasma Protein Therapeutics Market- By Immunoglobulin , By Value (USD Million), 2016-2026
Figure 9: Global Plasma Protein Therapeutics Market- By Albumin, By Value (USD Million), 2016-2026
Figure 10: Global Plasma Protein Therapeutics Market- By Factor VIII , By Value (USD Million), 2016-2026
Figure 11: Global Plasma Protein Therapeutics Market- By Others, By Value (USD Million), 2016-2026
Figure 12: Global Plasma Protein Therapeutics Market- By Application Market Share, 2020 & 2026
Figure 13: Global Plasma Protein Therapeutics Market- By Hemophilia, By Value (USD Million), 2016-2026
Figure 14: Global Plasma Protein Therapeutics Market- By PID, By Value (USD Million), 2016-2026
Figure 15: Global Plasma Protein Therapeutics Market- By ITP, By Value (USD Million), 2016-2026
Figure 16: Global Plasma Protein Therapeutics Market- By Others, By Value (USD Million), 2016-2026
Figure 17: Global Plasma Protein Therapeutics Market- By Region Market Share, 2020 & 2026
Figure 18: North America Plasma Protein Therapeutics Market Size, By Value, 2016-2026 (USD Million)
Figure 19: North America Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 20: North America Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 21: North America Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 22: North America Plasma Protein Therapeutics Market- By Product, By Value (USD Million), 2016-2026
Figure 23: North America Plasma Protein Therapeutics Market- By Application, By Value (USD Million), 2016-2026
Figure 24: Market Opportunity Chart of North America Plasma Protein Therapeutics Market- By Country, By Value (Year 2016-2026)
Figure 25: North America Plasma Protein Therapeutics Market- By Country Market Share, 2020 & 2026
Figure 26: United States Plasma Protein Therapeutics Market Size, By Value, 2016-2026 (USD Million)
Figure 27: United State Monthly Industry Aggregation Immunoglobulin (IG) Jan-June 2021 (In KG)
Figure 28: United State Monthly Industry Aggregation Plasma Derived Factor VIII Jan-June 2021 (In KG)
Figure 29: United State Monthly Industry Aggregation Albumin 25% Concentration Jan-June 2021 (In KG)
Figure 30: United State Plasma Protein Therapeutics Market- By Product, By Value (USD Million), 2016-2026
Figure 31: United State Plasma Protein Therapeutics Market- By Application, By Value (USD Million), 2016-2026
Figure 32: Canada Plasma Protein Therapeutics Market Size, By Value, 2016-2026 (USD Million)
Figure 33: Canada Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 34: Canada Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 35: Canada Urban population, 2015-2019 (In %)
Figure 36: Canada Plasma Protein Therapeutics Market- By Product, By Value (USD Million), 2016-2026
Figure 37: Canada Plasma Protein Therapeutics Market- By Application, By Value (USD Million), 2016-2026
Figure 38: Europe Plasma Protein Therapeutics Market Size, By Value, 2016-2026 (USD Million)
Figure 39: Europe Monthly Distribution - IVIG, Jan-May 2021 (In KG)
Figure 40: Europe Monthly Factor VIII Plasmatic SUPPLY ('000 i.u.), Jan-May 2021
Figure 41: Europe Monthly Distribution Albumin 20 - 25% SUPPLY Jan-May 2021 (In KG)
Figure 42: Europe Plasma Protein Therapeutics Market- By Product, By Value (USD Million), 2016-2026
Figure 43: Europe Plasma Protein Therapeutics Market- By Application, By Value (USD Million), 2016-2026
Figure 44: Market Opportunity Chart of Europe Plasma Protein Therapeutics Market- By Country, By Value (Year 2016-2026)
Figure 45: Europe Plasma Protein Therapeutics Market- By Country Market Share, 2020 & 2026
Figure 46: Germany Plasma Protein Therapeutics Market Size, By Value, 2016-2026 (USD Million)
Figure 47: Germany Monthly Distribution - IVIG, Jan-May 2021 (In KG)
Figure 48: Germany Monthly Factor VIII Plasmatic SUPPLY ('000 i.u.), Jan-May 2021
Figure 49: Germany Monthly Distribution Albumin 20 - 25% SUPPLY Jan-May 2021 (In KG)
Figure 50: Germany Plasma Protein Therapeutics Market- By Product, By Value (USD Million), 2016-2026
Figure 51: Germany Plasma Protein Therapeutics Market- By Application, By Value (USD Million), 2016-2026
Figure 52: United Kingdom Plasma Protein Therapeutics Market Size, By Value, 2016-2026 (USD Million)
Figure 53: United Kingdom Monthly Distribution - IVIG, Jan-May 2021 (In KG)
Figure 54: United Kingdom Monthly Factor VIII Plasmatic SUPPLY ('000 i.u.), Jan-May 2021
Figure 55: United Kingdom Monthly Distribution Albumin 20 - 25% SUPPLY Jan-May 2021 (In KG)
Figure 56: United Kingdom Plasma Protein Therapeutics Market- By Product, By Value (USD Million), 2016-2026
Figure 57: United Kingdom Plasma Protein Therapeutics Market- By Application, By Value (USD Million), 2016-2026
Figure 58: France Plasma Protein Therapeutics Market Size, By Value, 2016-2026 (USD Million)
Figure 59: France Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 60: France Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 61: France Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)
Figure 62: France Plasma Protein Therapeutics Market- By Product, By Value (USD Million), 2016-2026
Figure 63: France Plasma Protein Therapeutics Market- By Application, By Value (USD Million), 2016-2026
Figure 64: Spain Plasma Protein Therapeutics market Size, By Value, 2016-2026 (USD Million)
Figure 65: Spain Monthly Distribution - IVIG, Jan-May 2021 (In KG)
Figure 66: Spain Monthly Factor VIII Plasmatic SUPPLY ('000 i.u.), Jan-May 2021 (In KG)
Figure 67: Spain Monthly Distribution Albumin 20 - 25% SUPPLY (Kgs) Jan-May 2021 (In KG)
Figure 68: Spain Plasma Protein Therapeutics Market- By Product, By Value (USD Million), 2016-2026
Figure 69: Spain Plasma Protein Therapeutics Market- By Application, By Value (USD Million), 2016-2026
Figure 70: Asia Pacific Plasma Protein Therapeutics Market Size, By Value, 2016-2026 (USD Million)
Figure 71: Asia Pacific Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 72: Asia Pacific Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 73: Asia Pacific Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)
Figure 74: Asia Pacific Plasma Protein Therapeutics Market- By Product, By Value (USD Million), 2016-2026
Figure 75: Asia Pacific Plasma Protein Therapeutics Market- By Application, By Value (USD Million), 2016-2026
Figure 76: Market Opportunity Chart of APAC Plasma Protein Therapeutics Market- By Country, By Value (Year-2026)
Figure 77: APAC Plasma Protein Therapeutics Market- By Country Market Share, 2020 & 2026
Figure 78: China Plasma Protein Therapeutics Market Size, By Value, 2016-2026 (USD Million)
Figure 79: China Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 80: China Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 81: China Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)
Figure 82: China Plasma Protein Therapeutics Market- By Product, By Value (USD Million), 2016-2026
Figure 83: China Plasma Protein Therapeutics Market- By Application, By Value (USD Million), 2016-2026
Figure 84: Japan Plasma Protein Therapeutics Market Size, By Value, 2016-2026 (USD Million)
Figure 85: Japan Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 86: Japan Current Healthcare Expenditure as percentage of GDP, 2015-2018 (In %)
Figure 87: Japan Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)
Figure 88: Japan Plasma Protein Therapeutics Market- By Product, By Value (USD Million), 2016-2026
Figure 89: Japan Plasma Protein Therapeutics Market- By Application, By Value (USD Million), 2016-2026
Figure 90: Australia Plasma Protein Therapeutics market Size, By Value, 2016-2026 (USD Million)
Figure 91: Australia Current Healthcare Expenditure Per Capita, 2015-2018 (Current USD)
Figure 92: Australia Current Healthcare Expenditure as percentage of GDP, 2015-2018 (In %)
Figure 93: Australia Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)
Figure 94: Australia Plasma Protein Therapeutics Market- By Product, By Value (USD Million), 2016-2026
Figure 95: Australia Plasma Protein Therapeutics Market- By Application, By Value (USD Million), 2016-2026
Figure 96: South Korea Plasma Protein Therapeutics Market Size, By Value, 2016-2026 (USD Million)
Figure 97: South Korea Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 98: South Korea Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 99: South Korea Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)
Figure 100: South Korea Plasma Protein Therapeutics Market- By Product, By Value (USD Million), 2016-2026
Figure 101: South Korea Plasma Protein Therapeutics Market- By Application, By Value (USD Million), 2016-2026
Figure 102: Market Attractiveness Chart of Global Plasma Protein Therapeutics Market- By Product (Year-2016-2026)
Figure 103: Market Attractiveness Chart of Global Plasma Protein Therapeutics Market- By Application (Year 2016-2026
Figure 104: Market Attractiveness Chart of Global Plasma Protein Therapeutics Market- By Region (Year 2016-2026)
Figure 105: Global Plasma Protein Therapeutics company market share (%), 2020
Figure 106: CSL Behring Sales Revenues, 2016-2019 (USD Million)
Figure 107: CSL Behring Net Profit, 2016-2019 (USD Million)
Figure 108: CSL Behring Sales Revenue Split, By Business Segment (%), FY2019
Figure 109: CSL Behring Sales Revenue Split, By Geography Segment (%), FY2019
Figure 110: Baxter International Inc. Sales Revenues, 2016-2020 (USD Million)
Figure 111: Baxter International Inc. Gross Profit, 2016-2020 (USD Million)
Figure 112: Baxter International Inc. Sales Revenue Split, By Business Segment (%), FY2020
Figure 113: Baxter International Inc. Sales Revenue Split, By Geography Segment (%), FY2020
Figure 114: Takeda Pharmaceutical Company Limited Sales Revenues, 2016-2020 (USD Million)
Figure 115: Takeda Pharmaceutical Company Limited Net Income, 2016-2020 (USD Million)
Figure 116: Takeda Pharmaceutical Company Limited Sales Revenue Split, By Business Segment (%), FY2020
Figure 117: Takeda Pharmaceutical Company Limited Sales Revenue Split, By Geography Segment (%), FY2020
Figure 118: Biotest AG Sales Revenues, 2016-2020 (USD Million)
Figure 119: Biotest AG Gross Profit, 2016-2020 (USD Million)
Figure 120: Biotest AG Sales Revenue Split, By Business Segment (%), FY2020
Figure 121: Biotest AG Sales Revenue Split, By Geography Segment (%), FY2020
Figure 122: Bayer Group Sales Revenues, 2016-2020 (USD Million)
Figure 123: Bayer Group Net Profit, 2016-2020 (USD Million)
Figure 124: Bayer Group, By Business Segment (%), FY2020
Figure 125: Bayer Group, By Geographical Segment (%), FY2020
Figure 126: Grifols, S.A. Sales Revenues, 2016-2020 (USD Million)
Figure 127: Grifols, S.A. Sales Revenue Split, By Business Segment (%), FY2020
Figure 128: Grifols, S.A. Sales Revenue Split, By Business Segment (%), FY2020
Figure 129: Pfizer Annual Sales Revenue (USD Million), 2016-2020
Figure 130: Pfizer Annual Net Income/Loss (USD Million), 2016-2020
Figure 131: Pfizer sales Revenue, By Geographical Segment (%), FY2020
Figure 132: Octapharma USA Inc. Sales Revenues, 2016-2020 (USD Million)
Figure 133: Octapharma USA Inc. Net Profit, 2016-2020 (USD Million)
Figure 134: Kedrion Biopharma Sales Revenues, 2016-2020 (USD Million)
Figure 135: Kedrion Biopharma Sales Revenue Split, By Geography Segment (%), FY2020
Figure 136: ADMA Biologics, Inc. Sales Revenues, 2016-2020 (USD Million)
Figure 137: ADMA Biologics, Inc. Sales Revenue Split, By Business Segment (%), FY2020
List of Tables
Table A: Product Pipeline of Leading Plasma Protein Therapeutics Companies - Grifols S.A.
Table B: Product Pipeline of Leading Plasma Protein Therapeutics Companies - CSL Limited
Request Sample 
Request Discount 
Inquire Before Buy
